No Data
Hualan Biological Engineering, Inc. (002007.SZ): The company has obtained a single-sourced plasma collection license.
On December 4, Gelonghui reported that hualan biological engineering, inc. (002007.SZ) announced that on December 4, 2024, the company's wholly-owned subsidiary, hualan biological engineering chongqing co., ltd., received the "Plasma Collection License" issued by the Chongqing Municipal Health Committee for the hualan plasma collection station in Wushan County, Chongqing (hereinafter referred to as "Wushan Plasma Station"). The Wushan Plasma Station can officially begin plasma collection from the date it obtains the "Plasma Collection License." The operation of plasma collection at the Wushan Plasma Station will help enhance the company's supply capacity of raw plasma, which will have a positive impact on the company's long-term development.
Hualan Biological Engineering's Unit Gets Certificate for Cancer Drug's Registration
hualan biological engineering, inc. (002007.SZ): The genetic company has received the pharmaceutical registration certificate for the Ramucirumab injection.
On November 21, 2023, Hualan Biological Engineering, Inc. (002007.SZ) announced that on November 21, 2024, its affiliated company Hualan Gene Engineering Co., Ltd. (referred to as "Gene Company") obtained the "Drug Registration Certificate" for Bevacizumab Injection issued by the National Medical Products Administration. The Gene Company has been approved for Anbeiyou (Bevacizumab Injection), which is mainly used for the treatment of advanced, metastatic, or recurrent non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer, with the original manufacturer being Roche.
Hualan Biological Engineering (SZSE:002007) Sheds CN¥1.8b, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years
Earnings Miss: Here's What Hualan Biological Engineering Inc. (SZSE:002007) Analysts Are Forecasting For Next Year
Hualan Biological Engineering, Inc.: Third-quarter report of 2024.
Some Confidence Is Lacking In Hualan Biological Engineering Inc.'s (SZSE:002007) P/E
No Data
